Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Children with moderate-to-severe asthma treated with dupilumab were more than twice as likely to achieve clinical remission compared to placebo, according to a new analysis of the VOYAGE trial. The win ratio analysis showed consistent benefits across all four remission components — fewer exacerbations, normal lung function, and controlled asthma — regardless of baseline steroid dose. Experts say the findings could reshape how and when biologics are introduced in pediatric asthma care.
Children aged 6–11 with moderate-to-severe type 2 asthma treated with dupilumab were more than twice as likely to achieve clinical remission after one year compared to those on placebo, according to a post hoc win ratio analysis of the VOYAGE trial presented at the European Respiratory Society Congress. The analysis evaluated four remission components in hierarchical order: being exacerbation-free, having fewer exacerbations, achieving normal lung function, and maintaining controlled asthma.
The results held steady across both ICS dose groups — dupilumab patients won 68.2% of non-tied pairs in the high-dose group (win ratio: 2.14) and 69.8% in the medium-dose group (win ratio: 2.31). Experts noted that the consistency across baseline steroid intensity was particularly striking, suggesting robust efficacy regardless of prior maintenance therapy.
Key Takeaways:
Why it matters: Childhood is a critical window for lung development, and shifting the treatment goal from symptom control to full clinical remission could have long-term protective effects. These findings support earlier, more proactive use of biologics in pediatric asthma management.
